Search details
1.
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
N Engl J Med
; 388(12): 1080-1091, 2023 Mar 23.
Article
in English
| MEDLINE | ID: mdl-36920778
2.
Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001).
J Allergy Clin Immunol
; 153(4): 1040-1049.e12, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38157942
3.
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
N Engl J Med
; 384(12): 1101-1112, 2021 03 25.
Article
in English
| MEDLINE | ID: mdl-33761207
4.
Phosphorylated p38 MAP kinase expression by leucocytes is increased in allergic humans and associated with IgE responses.
Scand J Immunol
; 99(3): e13343, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38441376
5.
Navigating the atopic dermatitis toolbox: Challenging scenarios and shared decision-making.
Ann Allergy Asthma Immunol
; 132(3): 337-343, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38145707
6.
Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type.
Ann Allergy Asthma Immunol
; 132(3): 383-389.e3, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-37949351
7.
Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations.
Ann Allergy Asthma Immunol
; 132(3): 274-312, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38108679
8.
Safety and efficacy of eblasakimab, an interleukin 13 receptor α1 monoclonal antibody, in adults with moderate-to-severe atopic dermatitis: A phase 1b, multiple-ascending dose study.
J Am Acad Dermatol
; 90(3): 504-511, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-37866456
9.
Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study.
J Am Acad Dermatol
; 90(5): 945-952, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38340127
10.
Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.
J Am Acad Dermatol
; 90(2): e43-e56, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37943240
11.
Executive summary: Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies.
J Am Acad Dermatol
; 90(2): 342-345, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37943241
12.
More than just methylisothiazolinone: Retrospective analysis of patients with isothiazolinone allergy in North America, 2017-2020.
J Am Acad Dermatol
; 90(2): 319-327, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37879460
13.
Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial.
J Am Acad Dermatol
; 90(6): 1190-1199, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38296199
14.
Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis.
Dermatology
; 240(2): 243-253, 2024.
Article
in English
| MEDLINE | ID: mdl-38081155
15.
Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib.
Acta Derm Venereol
; 104: adv18452, 2024 May 06.
Article
in English
| MEDLINE | ID: mdl-38708991
16.
Real-world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study.
J Eur Acad Dermatol Venereol
; 38(2): 340-353, 2024 Feb.
Article
in English
| MEDLINE | ID: mdl-37669868
17.
Treat-to-target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitis.
J Eur Acad Dermatol Venereol
; 38(1): 42-51, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-37700595
18.
Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis.
J Drugs Dermatol
; 23(2): 23-28, 2024 Feb 01.
Article
in English
| MEDLINE | ID: mdl-38306128
19.
Comorbidities of atopic dermatitis-what does the evidence say?
J Allergy Clin Immunol
; 151(5): 1155-1162, 2023 05.
Article
in English
| MEDLINE | ID: mdl-36621338
20.
Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: A clinical review.
J Allergy Clin Immunol
; 2023 Dec 27.
Article
in English
| MEDLINE | ID: mdl-38154665